Immunoassay methods for prolactin detect macroprolactin (i.e. high molecular mass complexes of prolactin) to various degrees. Therefore it is generally assumed that the widely differing results by methods that measure both moieties to a differing extent are due to the presence of macroprolactin. We present a case which challenges such an assumption and suggest that precipitation by polyethylene glycol is the most reliable screen for identifying macroprolactin (and/or interfering antibodies if present).
Introduction
Prolactin can be present in serum in a variety of forms, including monomeric prolactin (mass 23 kDa) and macroprolactin, most frequently as a complex of prolactin and IgG (mass 150^170 kDa). 1 The di¡erent forms have di¡erent biological activity and macroprolactin appears to have little or no endocrine activity in vivo. 2^9 Therefore it has been generally assumed that to assess hypothalamicp ituitary function the most useful information for clinicians would be the monomeric prolactin concentration.
Di¡erent immunoassays detect macroprolactin to a variable extent. 10 It is important that the laboratory has a strategy to investigate samples with an elevated prolactin because macroprolactin can account for 5^25% of all cases of hyperprolactinaemia (depending on the assay used). 11 Gel ¢ltration chromatography (GFC) is impractical for all samples. Prolactin measurement following polyethylene glycol (PEG) precipitation of macroprolactin has been correlated with GFC for some methods, 12 but PEG is incompatible with some assay formulations. Comparison of results using methods with widely di¡ering responses to macroprolactin has also been employed, because a discrepancy would imply the presence of macroprolactin. However, we report a case in which this assumption is not valid.
Methods
Serum prolactin was assayed by a variety of methods. Our routine assay (AxSYM, Abbott Diagnostics) reacts strongly with macroprolactin, whereas the alternative method (Access 1, Beckman Coulter) usually reacts to a much smaller extent. All samples with elevated prolactin concentration in the AxSYM assay were assayed using the Access 1. All the results for a 4-month period are shown in Fig. 1 .
Other prolactin assays used the Bayer ACS-180 and Wallac Del¢a platforms. PEG precipitation and GFC were performed as described before. 12 Heterophilic antibody blocking tubes (SkyBio Ltd) were used as directed by the manufacturer.
Case report
LD, a 51-year-old woman, was investigated by her general practitioner for amenorrhoea of 6 years' duration. Serum follicle -stimulating hormone was 69 IU/L and luteinizing hormone 27 IU/L; serum prolactin, measured using the AxSYM assay, was also high, 2089 mIU/L (reference range 5500 mIU/L).
A repeat sample was requested as well as details of medications. A month later serum prolactin was 1992 mIU/L. Her medications included pimozide and procyclidine (known prolactin secretagogues) and Femulen (a progestogen-only contraceptive).
To check for macroprolactin the sample was assayed using the Access 1. Taking into account the bias between the two methods, the result of 747 mIU/L was lower than expected (see Fig. 1 ). This was provisionally ascribed to the presence of macroprolactin. However, PEG precipitation using the Wallac Del¢a assay showed 74% recovery of prolactin immunoreactivity excluding macroprolactin (recovery 460% excludes signi¢cant macroprolactinaemia). Therefore further studies were done. GFC revealed only monomeric prolactin when the fractions were assayed using the AxSYM, Access or Del¢a assays. Prolactin concentrations in both the AxSYM and Access assays were una¡ected by incubation with heterophilic antibodybinding tubes. In the AxSYM assay the sample showed linearity on dilution but there was a paradoxical increase in the Access assay: two-, four-and eightfold dilution yielded values of 1140, 1158 and 1150 mIU/L, respectively, compared with 747 mIU/L in the untreated sample.
The underlying cause of the hyperprolactinaemia was eventually con¢rmed as iatrogenic as serum concentrations became normal upon stopping medication (305 mIU/L using the AxSYM method).
In summary, this case describes drug-induced monomeric hyperprolactinaemia in which negative interference was seen with the Access method. Such interference was suspected following PEG precipitation (Wallac Del¢a) but only identi¢ed by serial dilution on the Access. Blocking studies using heterophilic antibody tubes were ine¡ective indicating that antibodies, if present, were not reactive/not heterophilic.
Discussion
It is clear that if PEG precipitation was the only procedure we used to investigate samples with an elevated prolactin there would have been no con£icting data. However, our routine assay (AxSYM), like some others, is unable to measure prolactin in PEG-treated serum. Therefore we have used method comparison to identify samples which apparently contain macroprolactin, although such samples are then referred for PEG studies. We do not report samples as macroprolactin-positive solely on the basis of method comparison data.
This particular sample gave a falsely low result in the Access assay. Because it was the second-line assay and an iatrogenic cause was suspected, this did not lead to inappropriate clinical management. In all follow-up investigations, apart from the lack of parallelism on dilution in the Access assay, the sample behaved as monomeric prolactin.We have been unable to identify what was present in the serum to give the anomalous result in the Access assay, but it does emphasize our concern that no single test can be relied on to identify interference in immunoassays. 13, 14 Developing a strategy to give a measure of monomeric prolactin is desirable in assessing the hypothalamic^pituitary^gonadal axis, and this may be particularly important in conditions in which macroprolactin is most prevalent, such as autoimmune disease and systemic lupus erythematosus in particular. 15 Emerging evidence suggests that the aetiopathogenesis of macroprolactin may be related to the function of prolactin as an in vivo modulator of cellular and humoral immunity 16^18 and not simply a posttranslational event. The choice of a routine assay that is insensitive to macroprolactin would mean that there is potential to miss useful information. It may not therefore be unreasonable that future use of prolactin assay takes into account the pros and cons of measuring both monomeric and macroprolactin moieties, with a reliable screening method to identify when macroprolactin is present.
Although PEG is employed to precipitate immunoglobulin-bound prolactin, it will also remove any other immunoglobulin which, if present, may interfere in the immunoassay, 19 thus enhancing the accuracy of monomeric prolactin measurement. The outcome of PEG precipitation has been compared with GFC by one of us (MNF-W), and within the data presented 12 there are examples which suggest that there are additional factors other than macroprolactin that in£uence the recovery of prolactin after PEG precipitation. In addition to doubling dilution, the use of heterophilic antibody-blocking tubes might further help identify patients with interfering antibodies, 14 even if macroprolactin is present. In a preliminary study of nine patients with signi¢cant macroprolactin levels (identi¢ed by PEG precipitation), there was no di¡erence in the prolactin concentration before and after incubation with heterophilic blocking tubes.
If an elevated prolactin is con¢rmed with a repeat sample, we suggest that PEG precipitation be used to obtain a measure of monomeric prolactin. Other approaches such as method comparison have limitations, as our case illustrates.
